This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-07. Anything still debated is marked as such rather than presented as settled.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
The effects are varied depending on the particular drug given. When anesthetists administer standard doses of these anesthetic drugs to a person with butyrylcholinesterase deficiency, the patient experiences prolonged paralysis of the respiratory muscles, requiring an extended period of time during which the patient must be mechanically ventilated. Eventually the muscle-paralyzing effects of these drugs will wear off despite the deficiency of the pseudocholinesterase enzyme. If the patient is maintained on a mechanical respirator until normal breathing function returns, there is little risk of harm to the patient. Because it is rare in the general population the deficiency is sometimes overlooked when a patient does not wake up after surgery. If this happens, there are two major complications that can arise. First, the patient may lie awake and paralyzed while medical providers try to determine the cause of the patient's unresponsiveness. Second, the breathing tube may be removed before the patient is strong enough to breathe properly, potentially causing respiratory arrest. This enzyme abnormality is a benign condition unless a person with burtyrylcholinesterase deficiency is exposed to the offending pharmacological agents.
24494Pu + 4820Ca → 292114Fl* → 290114Fl + 2 10n This reaction had been tried before, without success; for this 1998 attempt, JINR had upgraded all of its equipment to detect and separate the produced atoms better and bombard the target more intensely. One atom of flerovium, alpha decaying with lifetime 30.4 s, was detected. The decay energy measured was 9.71 MeV, giving an expected half-life of 2–23 s. This observation was assigned to 289Fl and was published in January 1999. The experiment was later repeated, but an isotope with these decay properties was never observed again, so the exact identity of this activity is unknown. It may have been due to the isomer 289mFl, but because the presence of a whole series of longer-lived isomers in its decay chain would be rather doubtful, the most likely assignment of this chain is to the 2n channel leading to 290Fl and electron capture to 290Nh. This fits well with the systematics and trends of flerovium isotopes, and is consistent with the low beam energy chosen for that experiment, though further confirmation would be desirable via synthesis of 294Lv in a 248Cm(48Ca,2n) reaction, which would alpha decay to 290Fl. The RIKEN team reported possible synthesis of 294Lv and 290Fl in 2016 in a 248Cm(48Ca,2n) reaction, but the alpha decay of 294Lv was missed, alpha decay of 290Fl to 286Cn was observed instead of electron capture to 290Nh, and the assignment to 294Lv instead of 293Lv was not certain. Glenn T.
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.
This step is the enzymatic transfer of a phosphate group from 1,3-bisphosphoglycerate to ADP by phosphoglycerate kinase, forming ATP and 3-phosphoglycerate. At this step, glycolysis has reached the break-even point: 2 molecules of ATP were consumed, and 2 new molecules have now been synthesized. This step, one of the two substrate-level phosphorylation steps, requires ADP; thus, when the cell has plenty of ATP (and little ADP), this reaction does not occur. Because ATP decays relatively quickly when it is not metabolized, this is an important regulatory point in the glycolytic pathway. ADP actually exists as ADPMg−, and ATP as ATPMg2−, balancing the charges at −5 both sides. Cofactors: Mg2+
In 1852, the British signed the Sand River Convention with the Boers, banning the sale of guns to Africans, while continuing to trade between themselves under the terms of the 1854 Bloemfontein Convention. The Boer Orange Free State was able to procure modern breech-loading rifles and a small amount of artillery. The Basuto were forced to rely on smuggled and locally-produced gunpowder, which was of inferior quality. In 1858, hostilities broke out between the Basuto and the Orange Free State. Inferior in both marksmanship and materiel, the Basuto suffered a series of defeats in wars that lasted until 1868. In 1866, the two sides signed the Treaty of Thaba Bosiu, whereby Moshoeshoe ceded most of his kingdom's arable land to the Boers. Hostilities resumed soon afterwards, and the Boers began employing a scorched earth policy, leading to starvation among the Basuto. The Basuto appealed to British High Commissioner for Southern Africa Sir Philip Wodehouse and the Colony of Natal for protection. Although, initially reluctant to intervene, on 12 March 1868 Wodehouse proclaimed Basutoland to be a royal dominion. The Basuto, who became part of the British Empire out of necessity, viewed any kind of colonial administration as "a snake in the house". The British saw it as their responsibility to westernize their new subjects. Wodehouse therefore supported a gradual introduction of colonial laws, so as not to provoke backlash from the Basuto. Basutoland's legal status remained unclear, with the Colonial Office at various times calling it a crown colony and a protectorate.
Sources: en.wikipedia.org
restriction fragment length polymorphism (RFLP) Variability within a population of organisms observed in the size of the restriction fragments produced when genomic DNA (or any particular DNA molecule) is digested by one or more restriction endonucleases. This variability results from a corresponding polymorphism in the locations of restriction sites within the molecule(s) due to slight differences in nucleotide sequence between individuals. RFLP is frequently exploited in the laboratory to construct physical maps of the genome, to identify the specific locus occupied by a particular gene, and to detect genetic differences between closely related individuals or determine that different samples originated from the same individual. Analysis of restriction fragments can also reveal the presence of a mutation that may itself cause disease or be closely linked to one that does.
An open-label pilot study on mild and moderate cases was performed in 2020, with mildly positive results. A phase III trial was performed in 2022 in China. In July 2022, China's drug regulator granted conditional approval for it to be used to treat COVID-19, following a local phase III trial. Initially, no detailed description of the said trial was published in any journals, but state media quoted some numbers from the developer: "40% clinical improvement in 7 days by FNC group, compared to 11% in control". It is unclear how such "improvement" is defined. Four phase III clinical trials investigated azvudine's efficacy and safety in adults with mild-to-moderate COVID-19. The findings indicate that azvudine may reduce the time to eliminate detectable levels of virus (viral load) and improve symptoms faster than standard treatment. In trials, it was reported to be safe with few side effects. However, some studies produced inconsistent results in terms of symptom improvement and severe illness prevention. Additionally, the studies tended to use a smaller number of participants than other major COVID-19 drug trials.
Russia launched a wave of missile attacks across Ukraine, killing at least 47 people. At least 33 people were killed in Kyiv, where the country's largest pediatric hospital was struck. Ten people were killed in Kryvyi Rih, while three were killed in Pokrovsk and one in Dnipro. Attacks were also reported in Kramatorsk and Sloviansk. The Ukrainian Air Force claimed to have shot down 30 of 38 missiles launched during the attacks. Ukraine and Poland signed a security agreement, forming a new volunteer unit called the Ukrainian Legion. The FSB claimed to have foiled a Ukrainian plot which involved a pilot attempting to hijack a Tu-22 bomber.
== External links == Canadian Society for medical Laboratory Science U.S. Department of Labor information on clinical laboratory technologists and technicians American Association for Clinical Chemistry American Society of Clinical Pathology American Society of Clinical Laboratory Science National Credentialing Agency for laboratory personnel National Accrediting Agency for Clinical Laboratory Science Medical Technologist Continuing Education AIMS: Australian Institute of Medical Scientists New Zealand Institute of Medical Laboratory Science Greek Association of Medical Laboratory Technologists Clinical laboratory scientists at work
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.